Immunic, Inc. (IMUX) stock
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.33+0.10 (+1.38%)
Close on Nov 17, 2026Market cap $100.01MP/E –Yield 0.00%
Immunic r&d expenses
Research and development expenses are spending on new products and technology.
Immunic's R&D Expenses for the twelve months ending Jun 30, 2026 was $90.64M, up 5.5% year over year. For fiscal 2025 it was $81.98M, up 2.4% from the year before. Over ten years it grew 7.5% a year on average. The highest annual figure on record is $83.22M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.98M | +2.4% |
| FY2024 | Dec 31, 2024 | $80.05M | -3.8% |
| FY2023 | Dec 31, 2023 | $83.22M | +16.8% |
| FY2022 | Dec 31, 2022 | $71.26M | +16.6% |
| FY2021 | Dec 31, 2021 | $61.12M | +58.2% |
| FY2020 | Dec 31, 2020 | $38.64M | +71.6% |
| FY2019 | Dec 31, 2019 | $22.51M | +134.6% |
| FY2018 | Dec 31, 2018 | $9.60M | -75.6% |
| FY2017 | Dec 31, 2017 | $39.34M | +30.9% |
| FY2016 | Dec 31, 2016 | $30.05M | -24.5% |
| FY2015 | Dec 31, 2015 | $39.77M | +0.7% |
| FY2014 | Dec 31, 2014 | $39.48M | +81.2% |
| FY2013 | Dec 31, 2013 | $21.79M | +327.4% |
| FY2012 | Dec 31, 2012 | $5.10M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $25.93M | +21.3% |
| Q1 FY2026 | Mar 31, 2026 | $25.63M | +19.0% |
| Q4 FY2025 | Dec 31, 2025 | $19.07M | -11.8% |
| Q3 FY2025 | Sep 30, 2025 | $20.01M | -6.4% |
| Q2 FY2025 | Jun 30, 2025 | $21.37M | +16.6% |
| Q1 FY2025 | Mar 31, 2025 | $21.53M | +14.9% |
| Q4 FY2024 | Dec 31, 2024 | $21.62M | +12.1% |
| Q3 FY2024 | Sep 30, 2024 | $21.37M | +8.0% |
| Q2 FY2024 | Jun 30, 2024 | $18.32M | -13.5% |
| Q1 FY2024 | Mar 31, 2024 | $18.74M | -18.4% |
| Q4 FY2023 | Dec 31, 2023 | $19.28M | -7.0% |
| Q3 FY2023 | Sep 30, 2023 | $19.80M | +19.7% |
| Q2 FY2023 | Jun 30, 2023 | $21.17M | +28.0% |
| Q1 FY2023 | Mar 31, 2023 | $22.96M | +31.6% |
| Q4 FY2022 | Dec 31, 2022 | $20.74M | +12.8% |
| Q3 FY2022 | Sep 30, 2022 | $16.54M | +6.8% |
| Q2 FY2022 | Jun 30, 2022 | $16.54M | +5.1% |
| Q1 FY2022 | Mar 31, 2022 | $17.45M | +51.4% |
| Q4 FY2021 | Dec 31, 2021 | $18.38M | +64.4% |
| Q3 FY2021 | Sep 30, 2021 | $15.48M | +40.2% |
| Q2 FY2021 | Jun 30, 2021 | $15.74M | +57.6% |
| Q1 FY2021 | Mar 31, 2021 | $11.52M | +79.0% |
| Q4 FY2020 | Dec 31, 2020 | $11.18M | +85.5% |
| Q3 FY2020 | Sep 30, 2020 | $11.04M | +55.4% |
| Q2 FY2020 | Jun 30, 2020 | $9.99M | +65.6% |
| Q1 FY2020 | Mar 31, 2020 | $6.43M | +91.8% |
| Q4 FY2019 | Dec 31, 2019 | $6.03M | +42.0% |
| Q3 FY2019 | Sep 30, 2019 | $7.10M | +403.7% |
| Q2 FY2019 | Jun 30, 2019 | $6.03M | +179.5% |
| Q1 FY2019 | Mar 31, 2019 | $3.36M | -67.0% |
| Q4 FY2018 | Dec 31, 2018 | $4.25M | -58.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.41M | -85.4% |
| Q2 FY2018 | Jun 30, 2018 | $2.16M | -78.1% |
| Q1 FY2018 | Mar 31, 2018 | $10.16M | +5.5% |
| Q4 FY2017 | Dec 31, 2017 | $10.19M | +15.0% |
| Q3 FY2017 | Sep 30, 2017 | $9.69M | +29.7% |
| Q2 FY2017 | Jun 30, 2017 | $9.83M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.86M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.47M | – |
See a number that looks wrong?